
The FDA is seeking public feedback on how to regulate generative AI in medical devices, recognizing both its promise and risks.
Key Details
- 1FDA has released a discussion paper on regulatory approaches for generative AI in medical devices.
- 2The agency is focusing on risk assessment, premarket evaluation, and postmarket safety monitoring.
- 3Radiologist Rick Abramson, MD, now heads the FDA Digital Health Center and emphasizes the need for leadership in this area.
- 4Comments are invited from stakeholders including physicians, device makers, and researchers until October 19.
- 5The FDA aims for a nimble, risk-based, and minimally burdensome regulatory approach.
Why It Matters

Source
Radiology Business
Related News

Pennsylvania Bill Mandates AI Use Disclosure in Healthcare Facilities
Pennsylvania House passes a bill requiring healthcare facilities, including imaging centers, to disclose their use of AI in clinical care.

Radiology Societies Urge Patient Safety in FDA Generative AI Regulation
RSNA and ACR call for patient safety and ongoing monitoring as the FDA considers regulations for generative AI in radiology.

HPI Rebuts AI's Supposed Impact on Radiology Workforce Shortage
Harvey L. Neiman HPI challenges recent claims that AI has lessened the radiology workforce burden, citing evidence of rising workloads and imaging volumes.